KRAS and neoplasm: Since KRAS represents a reliable tumor burden surrogate for PDAC (seen in close to 95% of PDAC) it was decided to perform ultrasensitive droplet digital PCR (ddPCR) in the complete series of 15 blood based liquid biopsies [1].